Matrix metalloproteinase inhibitor COL-3 prevents the development of paclitaxel-induced hyperalgesia in mice

Medical Principles and Practice

Volumn 22, Issue 1, 2012, Pages 35-41

  Parvathy, Subramanian S ^a   Masocha, Willias ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Chemically modified tetracycline; Chemokine; Chemotherapy induced peripheral neuropathy; COL 3; Cytokine; Matrix metalloproteinase inhibitor; Paclitaxel; Pain; Prevention

Indexed keywords

CD11B ANTIGEN; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INCYCLINIDE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; DRUG EFFECT; FEMALE; GENETIC TRANSCRIPTION; HOT PLATE TEST; HYPERALGESIA; IMMUNOMODULATION; LATENT PERIOD; MICROGLIA; MOUSE; NEUROPATHIC PAIN; NONHUMAN; SPINAL CORD; SPLEEN; THERMAL STIMULATION;

ANIMALS; ANTIGENS, CD11B; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN; CHEMOKINES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; HYPERALGESIA; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, INBRED BALB C; PACLITAXEL; POLYMERASE CHAIN REACTION; SPINAL CORD; SPLEEN; TETRACYCLINES;

EID: 84871715717     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000341710     Document Type: Article

References (30)

1. Luqmani YA: Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005; 14(suppl 1):35-48. (Pubitemid 41161048)
2. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM: Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006; 72: 151-169.
3. Polomano RC, Bennett GJ: Chemotherapyevoked painful peripheral neuropathy. Pain Med 2001; 2: 8-14.
4. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR: Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004; 109: 132-142. (Pubitemid 38479779)
5. Callizot N, Andriambeloson E, Glass J, Revel M, Ferro P, Cirillo R, Vitte PA, Dreano M: Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity. Cancer Chemother Pharmacol 2008; 62: 995-1007.
6. Nieto FR, Entrena JM, Cendan CM, Pozo ED, Vela JM, Baeyens JM: Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain 2008; 137: 520-531. (Pubitemid 351970170)
7. Smith BH, Elliott AM, Hannaford PC: Is chronic pain a distinct diagnosis in primary care? Evidence arising from the Royal College of General Practitioners' Oral Contraception study. Fam Pract 2004; 21: 66-74. (Pubitemid 38240343)
8. Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW: An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007; 1168: 46-59. (Pubitemid 47320623)
9. Zhang H, Yoon SY, Dougherty PM: Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J Pain 2012; 13: 293-303.
10. Burgos E, Gomez-Nicola D, Pascual D, Martin MI, Nieto-Sampedro M, Goicoechea C: Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. Eur J Pharmacol 2012; 682.62-72.
11. Ledeboer A, Jekich BM, Sloane EM, Mahoney JH, Langer SJ, Milligan ED, Martin D, Maier SF, Johnson KW, Leinwand LA, Chavez RA, Watkins LR: Intrathecal interleukin-10 gene therapy attenuates paclitaxelinduced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun 2007; 21: 686-698. (Pubitemid 46829773)
12. Chen Y, Yang C, Wang ZJ: Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 2011; 193: 440-451.
13. Nishida K, Kuchiiwa S, Oiso S, Futagawa T, Masuda S, Takeda Y, Yamada K: Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxelinduced neuropathy. Cancer Sci 2008; 99: 1618-1625.
14. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR: Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991; 2: 297-321.
15. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, Sorsa T: In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: Relationship to bone and cartilage degradation. Bone 1998; 22: 33-38. (Pubitemid 28033650)
16. Gu Y, Lee HM, Golub LM, Sorsa T, Konttinen YT, Simon SR: Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines. Ann Med 2005; 37: 450-460. (Pubitemid 41476130)
17. Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-110. (Pubitemid 13058546)
18. Masocha W, Robertson B, Rottenberg ME, Mhlanga J, Sorokin L, Kristensson K: Cerebral vessel laminins and IFN-gamma define Trypanosoma brucei brucei penetration of the blood-brain barrier. J Clin Invest 2004; 114: 689-694. (Pubitemid 39578759)
19. Masocha W: Systemic lipopolysaccharide (LPS)-induced microglial activation results in different temporal reduction of CD200 and CD200 receptor gene expression in the brain. J Neuroimmunol 2009; 214: 78-82.
20. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(Ydelta delta C(T)) Method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
21. Liu CC, Lu N, Cui Y, Yang T, Zhao ZQ, Xin WJ, Liu XG: Prevention of paclitaxel-induced allodynia by minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain 2010; 6: 76.
22. Acharya MR, Venitz J, Figg WD, Sparreboom A: Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat 2004; 7: 195-208. (Pubitemid 39024520)
23. Gu Y, Lee HM, Simon SR, Golub LM: Chemically modified tetracycline-3 (CMT-3): A novel inhibitor of the serine proteinase, elastase. Pharmacol Res 2011; 64: 595-601.
24. Spooren A, Kolmus K, Laureys G, Clinckers R, De Keyser J, Haegeman G, Gerlo S: Interleukin-6, a mental cytokine. Brain Res Rev 2011; 67: 157-183.
25. Milligan ED, Sloane EM, Watkins LR: Glia in pathological pain: A role for fractalkine. J Neuroimmunol 2008; 198: 113-120.
26. Lokeshwar BL: Chemically modified nonantimicrobial tetracyclines are multifunctional drugs against advanced cancers. Pharmacol Res 2011; 63: 146-150.
27. Richards C, Pantanowitz L, Dezube BJ: Antimicrobial and non-antimicrobial tetracyclines in human cancer trials. Pharmacol Res 2011; 63: 151-156.
28. Chu QS, Forouzesh B, Syed S, Mita M, Schwartz G, Cooper J, Curtright J, Rowinsky EK: A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 2007; 25: 359-367. (Pubitemid 46944843)
29. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM: Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS Malignancy Consortium Study. J Clin Oncol 2006; 24: 1389-1394. (Pubitemid 46622003)
30. Fingleton B: CMT-3. CollaGenex. Curr Opin Investig Drugs 2003; 4: 1460-1467.